April 2023 in “Journal of The American Academy of Dermatology” This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.
April 2020 in “Journal of the Endocrine Society” In this case study, the use of somatostatin analogues was effective in localizing and confirming a neuroendocrine lung tumor as the source of ectopic ACTH syndrome, leading to marked clinical improvement in a patient unable to undergo surgery.
9 citations
,
January 1997 in “Gynecological Endocrinology” This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.
6 citations
,
October 2015 in “Clinical Case Reports” This study highlights that scalp hair loss is an underreported side effect of somatostatin analogs therapy, potentially linked to decreased GH/IGF-1 levels or a direct drug effect.
November 2013 in “John Wiley & Sons, Ltd eBooks” This chapter reviews various mucocutaneous manifestations of endocrine disorders and provides illustrative images of these clinical features, but reports no new research findings.